SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-024937
Filing Date
2023-03-31
Accepted
2023-03-31 06:07:23
Documents
15
Period of Report
2023-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea176126-8k_adialpharma.htm   iXBRL 8-K 29853
2 PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., DATED MARCH 30, 2023 ea176126ex99-1_adialpharma.htm EX-99.1 22533
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3998
  Complete submission text file 0001213900-23-024937.txt   283386

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adil-20230330.xsd EX-101.SCH 3702
5 XBRL DEFINITION FILE adil-20230330_def.xml EX-101.DEF 26516
6 XBRL LABEL FILE adil-20230330_lab.xml EX-101.LAB 36424
7 XBRL PRESENTATION FILE adil-20230330_pre.xml EX-101.PRE 25140
9 EXTRACTED XBRL INSTANCE DOCUMENT ea176126-8k_adialpharma_htm.xml XML 5255
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

IRS No.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 23783029
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences